Table 1. Select adjuvant immunotherapy trials for the treatment of resected NSCLC.
| Trial identifier (estimated primary completion) | Study name and sponsor | Phase | Intervention | Estimated enrollment | Stage | Primary endpoints |
|---|---|---|---|---|---|---|
| NCT02486718 (Nov. 2020) | IMpower010, Hoffman-La Roche (USA) | III | Atezolizumab vs. best supportive care | 1,280 | IB–IIIA (v7) | DFS |
| NCT02504372 (Aug. 2021) | KEYNOTE-091/PEARLS, Merck (USA) | III | Pembrolizumab vs. placebo | 1,080 | IB–IIIA (v7) | DFS |
| NCT02273375 (Jan. 2023) | BR31, Canadian Cancer Trials Group (Canada) | III | Atezolizumab vs. placebo | 1,360 | IB–IIIA (v7) | DFS |
| NCT02595944 (Jul. 2024) | ANVIL, NCI (USA) | III | Nivolumab vs. observation | 903 | IB–IIIA (v7) | DFS, OS |
NSCLC, non-small cell lung cancer; DFS, disease-free survival; NCI, National Cancer Institute; OS, overall survival.